Complexes of dermatan sulfate and drugs, giving improved pharmacokinetics
CA 2208566 A1 · Owner: Access Pharmaceuticals, Inc. · Inventors: Ranney, David F.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A drug carrier composition comprising a drug complexed with dermatan sulfate is disclosed. The drug is preferably an antitumor drug and may be taxol a , peptide onco-agent or vincristine. The most preferred antitumor drug is doxorubicin. The dermatan sulfate is essentially purified dermatan sulfate with a sulfur content of up to 9 % (w/w) and with selective oligosaccharide oversulfation. The compositions are administered in a fashion that allows efficient vascular access and induced the following in vivo effects: 1) rapid partial or total endothelial envelopment of the drug (diagnostic) carrier; 2) sequestration of the carrier and protection of the entrapped agent from blood vascular …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 22, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 22, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 22, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.